Results 171 to 180 of about 264,642 (338)

HIFU‐Driven Targeted Pyroptosis Therapy in Basal‐Like Breast Cancer

Advanced Science, EarlyView.
This study presents a HIFU‐driven pyroptosis strategy for BLBC treatment. Combining HIFU with platelet‐membrane hybridized liposomes encapsulating mitoxantrone enhances tumor targeting and efficacy. The synergistic treatment modulates key epigenetic regulators and activates the pyroptotic pathway through ROS generation and inflammasome signaling ...
Xiaomin Su, Yang Wang, Xifeng Qin, Yaqiong Xiao, Boshu Ouyang, Lina Hu, Lin Kang, Ruizhe Xu, Ce Xu, Zanya Sun, Chenyu Sun, Huishu Guo, Zhiqing Pang, Shun Shen   +13 more
wiley   +1 more source

Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature [PDF]

, 2019
Immune checkpoint inhibitors are used to treat numerous malignancies but may be associated with severe adverse events. Bullous dermatoses, chiefly bullous pemphigoid (BP), are potentially progressive adverse events that cause blistering skin lesions and ...
Choi, Jennifer N, Kosche, Cory, Owen, Joshua L, Sadowsky, Lauren M   +3 more
core  

PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3 [PDF]

, 2010
Sabine J. Wölfle, Julia Strebovsky, Holger Bartz, Aline Sähr, Caroline Arnold, Claus Kaiser, Alexander H. Dalpke, Klaus Heeg   +7 more
openalex   +1 more source

Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy

Advanced Science, EarlyView.
A vitiligo‐derived gene signature predicts response to immune checkpoint blockade across multiple cancer cohorts, providing a framework for patient stratification. Building on this, Fulvestrant—a clinically approved estrogen receptor degrader—further enhances antitumor immunity by reprogramming tumor‐associated macrophages and promoting CD8⁺ T cell ...
Jie Zhu, Liting Huang, Suzhen Bi, WeiKaixin Kong, Wanting Feng, Yingjia Li, Zhengwei Xie, Peipei Shan, Sujie Zhu   +8 more
wiley   +1 more source

PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer

Nature Communications
Resistance to radiotherapy is a major barrier during cancer treatment. Here using genome-scale CRISPR/Cas9 screening, we identify CD274 gene, which encodes PD-L1, to confer lung cancer cell resistance to ionizing radiation (IR).
Zhen Shu, Bhakti Dwivedi, Jeffrey M. Switchenko, David S. Yu, Xingming Deng   +4 more
doaj   +1 more source

DICHOTOMY OF PD-L1 AND PD-L2 PATHWAYS IN NEGATIVELY REGULATING ALLOREACTIVE CD4+ AND CD8+ T CELLS

, 2004
Reshma Kewalaramani, Duc Vu, Mohamed H. Sayegh, X C. Li   +3 more
openalex   +1 more source

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors [PDF]

, 2010
Céline Berthon, Virginie Driss, Jizhong Liu, Klaudia Kuranda, Xavier Leleu, Nathalie Jouy, Dominique Hétuin, Bruno Quesnel   +7 more
openalex   +1 more source

CMTM6 controls PD-L1 [PDF]

Nature Immunology, 2017
openaire   +2 more sources

A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors

Advanced Science, EarlyView.
A modular antimicrobial‐peptide‐based therapeutic system integrating membrane‐targeted selectivity, a conformation‐driven polyethylene glycolylated blocker, and serum‐stabilizing N‐cap is developed. The optimized conjugate 270 shows potent, rapid killing of the desired tumor cells, high serum stability, low off‐target toxicity, and broad applicability,
Tianxing Liu, Lingyu Ke, Ruize Sun, Xiaoling Chen, Mei Zhou, Olaf R. P. Bininda‐Emond, Chengbang Ma, Yangyang Jiang, Tao Wang, Chris Shaw, Lei Wang, Tianbao Chen, Alideertu Dong   +12 more
wiley   +1 more source

ABSOLUTE REQUIREMENT FOR THE PD-1/PD-L1 PATHWAY FOR COSTIMULATION BLOCKADE-INDUCED ALLOGRAFT TOLERANCE.

, 2006
NULL AUTHOR_ID
openalex   +1 more source